OmniAb shareholders elect two directors at annual meeting

OmniAb, Inc. (NASDAQ:OABI) announced the results of its 2025 Annual Meeting of Shareholders held on Tuesday. The company, currently trading at $1.65 and showing Fair financial health according to InvestingPro analysis, has seen its shares decline over 50% year-to-date. According to an SEC filing, shareholders elected two Class III directors to serve three-year terms expiring at the 2028 Annual Meeting.

Carolyn R. Bertozzi, Ph.D., received 36,153,128 votes in favor and 31,275,065 votes withheld, while John Higgins secured 53,835,964 votes in favor and 13,592,229 votes withheld. Both elections had 16,933,628 broker non-votes.

Shareholders also ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal received overwhelming support with 84,233,643 votes in favor, 110,544 against, and 17,634 abstentions.

OmniAb, an emerging growth company based in Emeryville, California, filed the voting results in an 8-K form with the Securities and Exchange Commission on Wednesday. The company specializes in commercial physical and biological research services. With a market cap of $208 million, OmniAb maintains a strong liquidity position with its current ratio of 4.7 and is scheduled to report its next earnings on August 7, 2025. Discover more detailed insights and 8 additional ProTips about OmniAb’s financial outlook in the comprehensive InvestingPro Research Report.

In other recent news, OmniAb Inc. reported its first-quarter 2025 earnings, revealing a revenue increase to $4.2 million, up from $3.8 million in the same period last year. The company also reported a net loss of $18.2 million, an improvement from the previous year’s $19 million loss, as a result of effective cost-control measures. OmniAb has set a revenue guidance of $20-25 million for 2025, reflecting optimism in its ongoing projects. The company has also revised its operating expense guidance downward, indicating effective cost management strategies.

Additionally, OmniAb launched the Exploration Partner Access Program, allowing partners to purchase exploration instruments for use in their labs. This program is expected to create new revenue streams for the company. Meanwhile, the company continues to expand its partner ecosystem, with 95 active partners as of the first quarter. The recent deal with Angelini Pharma for a small molecule ion channel modulator is notable, with OmniAb expecting to receive a $3 million upfront payment and potential milestone payments. These developments underscore OmniAb’s focus on innovation and growth in the biopharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.